Palvella Therapeutics, Inc Asset Resilience Ratio
Palvella Therapeutics, Inc asset resilience ratio. Palvella Therapeutics, Inc (PVLA) has an Asset Resilience Ratio of 24.76% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Palvella Therapeutics, Inc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Palvella Therapeutics, Inc (None–None)
Asset resilience ratio of Palvella Therapeutics, Inc from None to None. This chart shows how Palvella Therapeutics, Inc's Asset Resilience Ratio has changed over time. Read total liabilities of Palvella Therapeutics, Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Palvella Therapeutics, Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Palvella Therapeutics, Inc's balance sheet.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $62.78 Million | 24.76% |
| Total Liquid Assets | $62.78 Million | 24.76% |
Asset Resilience Insights
- Good Liquidity Position: Palvella Therapeutics, Inc maintains a healthy 24.76% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Palvella Therapeutics, Inc Industry Peers by Asset Resilience Ratio
Compare Palvella Therapeutics, Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
Palvella Therapeutics, Inc Asset Resilience Ratio by Year (None–None)
Palvella Therapeutics, Inc asset resilience ratio by year from None to None. The table below shows the annual Asset Resilience Ratio data for Palvella Therapeutics, Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| No yearly data available. | ||||
About Palvella Therapeutics, Inc
Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 cl… Read more